Skip to main content
. 2017 Dec 20;3(12):e1701629. doi: 10.1126/sciadv.1701629

Fig. 4. In vivo clinical trials.

Fig. 4

(A) Paper battery being attached to the skin surface for ETC measurement (left), with HA sprayed under the paper battery anode (right). (B) Amperometric I-t result recorded from the biosensor attached to the skin surface. (C) Biosensing response current with (red) and without (blue) the ETC control test. (D) In vivo invasive blood glucose measurement by using a finger-prick glucometer (left) and a venous blood test with vein detained needles (right). (E) Results of hourly glucose monitoring in 1-day period from 10:00 to 23:00 by using a glucometer (red) and ETC devices (blue) (subject 1). (F) Results of 5-day glucose monitoring with the glucometer (red) and ETC devices (blue) (subject 1). (G) Results of blood glucose measured by using a plasma blood test with a vein detained needle (red) and ETC devices (blue) during the OGTT (subjects 2 and 3).